
Index

A

- Abnormal involuntary movement scale (AIMS), 431
- Acute bipolar depression
 - add-on treatment (*see* Add-on treatment, acute bipolar depression)
 - combination treatment, 543–544
 - endogenous/melancholic unipolar depression, 530
 - meta-analytic studies, 552–555
 - monotherapy (*see* Monotherapy, acute bipolar depression)
 - post hoc studies
 - antidepressants, 552
 - aripiprazole, 552
 - olanzapine and OFC, 551
 - quetiapine, 551–552
 - ziprasidone, 552
 - treatment options, 540–543
- Acute mania
 - add-on treatment (*see* Add-on treatment, acute mania)
 - agents (*see* Agents, acute mania)
 - combination treatment
 - carbamazepine, 517–518
 - description, 517
 - FGAs, 518
 - haloperidol, 519
 - lithium, 519–520
 - risperidone, 521
 - valproate, 520–521
 - meta-analyses, 527–530
 - monotherapy (*see* Monotherapy)
 - post hoc analyses
 - aripiprazole, 527
 - asenapine, 526–527
 - lithium, 527
 - olanzapine, 525–526
 - quetiapine, 526
 - risperidone, 526
 - ziprasidone, 527
- Addiction severity index (ASI), 432
- Add-on treatment, acute bipolar depression
 - ECT, 550
 - lamotrigine, 550
 - levetiracetam, 551
 - lithium
 - antidepressant augmentation in bipolar patients, 546
 - carbamazepine, 546
 - efficacy and safety, 544
 - lamotrigine group, 545
 - lithium plus paroxetine vs. paroxetine, 545–546
 - L-sulpiride, 545
 - paroxetine vs. imipramine vs. placebo, 545
 - placebo-controlled adjunctive study, 547–548
 - and valproate, 546–547
 - lurasidone, 551
 - modafinil group, 550
 - mood stabilizer, 548–549
 - omega-3 fatty acids, 550
 - paroxetine/bupropion, 550–551
 - transcranial magnetic stimulation, 550
- Add-on treatment, acute mania
 - ECT, 524
 - haloperidol, 521
 - lithium
 - carbamazepine, 522
 - oxcarbazepine, 522

- Add-on treatment, acute mania (*cont.*)
 and valproate, 522–524
 and valproate/carbamazepine, 524
 and valproate/carbamazepine/
 antipsychotics, 524
 manic patients with insomnia, 524–525
 valnoctamide *vs.* placebo, 525
- ADHD. *See* Attention deficit hyperactivity disorder (ADHD)
- Aetiopathogenesis
 autoimmune thyroiditis, 301
 biological *vs.* psychological, 40
 description, 389
 neurobiology (*see* Neurobiology)
 paediatric BD
 low premorbid IQ, 667
 marital conflict, 666
 non-shared environmental factors, 666
 obstetric complications, 667
 schizophrenia, 667
 theoretical approach, 666
 traditional approach, 666
 psychological theories, 390–393
 social theories, 389–390
- Agents, acute mania
 antiepileptics, 510
 antipsychotics, 516
 carbamazepine *vs.*
 haloperidol, 509
 lithium, 509
 patients, 509
 valproate, 509
 depressive symptoms, 517
 ECT methods, 516
 haloperidol *vs.*
 aripiprazole, 512, 513
 carbamazepine, 510, 513
 international multicentre study, 511
 MADRS score, 512
 olanzapine, 510–511
 quetiapine, 511
 risperidone, 511–512
 ziprasidone, 512–513
 lithium *vs.*
 aripiprazole, 506–507
 carbamazepine, 503–504
 chlorpromazine, 504
 divalproex arm dropped out, 503
 haloperidol, 504–505
 lamotrigine, 504
 olanzapine, 505
 quetiapine, 505–506
 valproate, 502–503
 olanzapine *vs.*
 asenapine, 514
 lithium, 514
 risperidone, 514–515
 ziprasidone, 515
 patients enrolled in RCTs, 517
 quetiapine *vs.*
 haloperidol, 516
 lithium, 515
 paliperidone, 515, 516
 valproate *vs.*
 carbamazepine, 507
 divalproex *vs.* oxcarbazepine, 508–509
 lithium, 507
 MADRS score, 508
 olanzapine, 507–508
 oxcarbazepine, 509
 YMRS scores, 508
- AIMS. *See* Abnormal involuntary movement scale (AIMS)
- Alcohol use disorders
 aripiprazole, 215
 clinical feature, 212
 epidemiology, 206
 hypomania, 211, 212
 self-healing method, 211–212
 smoking, 213
 sociodemographic factors, 212
- Alcohol use disorders identification test (AUDIT), 431–432
- Alzheimer's disease, 282
- American Psychiatric Association (APA) treatment
 antidepressants, 645
 benzodiazepines and neuroleptics, 645
 categories, guidelines, 646
 mood stabilizer, 646
 olanzapine monotherapy, 646
 Steering Committee on Practice Guidelines, 645
 types, medications, 645
 valproate and carbamazepine, 645
- Anorexia nervosa (AN), 257
- Antiepileptics
 carbamazepine, 467–468, 483–485
 description, 466
 efficacy, 485
 eslicarbazepine, 485
 lamotrigine, 468, 485
 topiramate, 485
 valproate, 467, 480–483
- Antipsychotics
 aripiprazole, 493–495
 asenapine, 498–499

- cariprazine, 500–501
 efficacy, chlorpromazine, 486
 haloperidol, 486–488
 medication, 275
 olanzapine, 488–491
 paliperidone, 499–500
 primary indication, 486
 quetiapine, 491–493
 risperidone, 495–496
 ziprasidone, 496–498
- Antisocial PD (ASPD), 198–200
- Anxiety
 disorder, 230, 232–234
 GAD, 230, 231, 235–237
 and impulsivity in BD patients, 231
 manic symptoms, 230
 panic disorder, 237–240
 patients, 230–231
 psychiatric patients, 230
 PTSD, 246–248
 simple (specific) phobia, 237, 241, 242
 social anxiety disorder (social phobia),
 241, 243–246
 unipolar depression, 231
- Artefactual comorbidity, 225
- ASI. *See* Addiction severity index (ASI)
- ASPD. *See* Antisocial PD (ASPD)
- Attention deficit hyperactivity disorder
 (ADHD), 227, 250–256, 665–666
 anxiety disorder, 227, 254
 behavioural disorder, 666
 paediatric disorder, 250
 refractory depression, 254
- AUDIT. *See* Alcohol use disorders
 identification test (AUDIT)
- B**
- BD. *See* Bipolar disorder (BD)
- BDNF. *See* Brain-derived neurotrophic
 factor (BDNF)
- Bech–Rafaelsen mania rating scale (MRS), 425
- Beck depression inventory (BDI-I), 424
- BED. *See* Binge eating disorder (BED)
- Behavioural disorder
 impulsive behaviour, 70
 logorrhoea, 70
- Bell's mania, 47, 58, 59
- Berkson's bias, 225
- Bifrontal ECT (BFECT), 516
- Binge eating disorder (BED), 257
- Biological therapies
 acute bipolar depression (*see* Acute bipolar
 depression)
- acute mania (*see* Acute mania)
- 'anergic depression', 591
- antidepressants, 469–470
- antiepileptics (*see* Antiepileptics)
- antimanic agent, 590
- antipsychotics, 469
- comorbid conditions
 agitation, treatment, 586–587
 and anxiety disorders, 585
 neurocognitive deficit, treatment, 587
 SUD, 584–585
 suicide, 587
 weight gain, 585–586
- comorbid OCD, 592
- double-blind RCTs, 591
- FGAs, 592–593
- genetic study, BD-I and BD-II
 patients, 592
- imipramine group, 591–592
- lithium, 461–466
- maintenance treatment (*see* Maintenance
 treatment)
- mixed episodes (*see* Mixed episodes)
- pharmaceutical treatment, 587–590
- PORT method, 470, 471
- rapid cycling patients (*see* Rapid cycling
 BD patients)
- SGAs, 593
- SSRIs, 593
- STEP-BD patients, 590
- switching and antidepressant
 treatment, 592
- treatment
 acute bipolar depression, 470, 474
 acute bipolar mania, 470–472, 482
 BD-I and BD-II patients, 470, 473
 comorbid anxiety, 470, 478
 maintenance, 470, 475
 patients and the risk, 470, 476
 rapid cycling patients, 470, 477
 venlafaxine vs. bupropion, 591
- Bipolar depression
 activity and behaviour, 36–37
 agitation, 36
 anorexia and weight loss, 39
 classification efforts, 40–41
 decreased sexual desire, 39–40
 delusions, 37–38
 depersonalization and derealization, 36
 hallucinations, 38
 'hysteroid dysphoria', 41
 irritability, 36
 'melancholia gravis', 40
 mood and anhedonia, 35–36

- Bipolar depression (*cont.*)
 non-endogenous, 41
 pseudounipolar patients, 42
 signs and symptoms, 43
 sleep disturbance, 39
 somatic functions, disturbance, 38–39
 suicide, 38
 thought disorder, 37
 unipolar depressed patients, 42–43
- Bipolar disorder (BD)
 alcohol and drug use, 60
 BD-II patients
 vs. BD-I, 132
 depressed unmedicated vs. medicated, 132–133
 healthy controls, 131
 IQ, 132
 classification systems, 32
 depression (*see* Bipolar depression)
 hypomania (*see* Hypomania)
 intensity and duration, 31
 long-term treatment, patients (*see* Long-term course, BD patients)
 mania (*see* Mania)
 mixed episodes (*see* Mixed episodes) and mood episodes, 33
 multiple clinical aspects, 32, 33
 neurocognitive functions (*see* Neurocognitive functions)
 normal mood, 31
 pathological mood, 31–32
 psychotic features (*see* Psychotic features)
 'rapid cycling', 34–35
 subjective experience, 60–62
 subsyndromal depressive symptoms, 59–60
 symptoms, 62–64
- Bipolar spectrum
 antidepressant-induced switch, 183
 anxiety and dysphoric symptoms, 183–184
 BD-II patients, 131
 BPD, 200, 201
 chronic conditions, 182–183
 classification, 181–182
 clinical and epidemiological data, 182, 184
 comorbidity, BD, 185
 cyclothymic disorder, 183
 epidemiology, 354–355
 geographical instability, 183
 HCL-32, 425
 hypomania and depression, 185
 mood swings, 182, 183
 noise, 183
 obesity, 262
 obsessive spectrum, 249
 phenomenological similarity, 184
 polysubstance abuse, 183
 primary bipolar subtypes, 185–186
 pseudounipolar, 183
 psychopathology and diagnosis, 182
 schizophrenia and affective disorders, 181
 subthreshold bipolarity, 182
 tobacco and coffee, 206
 traditional bipolar vs. unipolar distinction, 181
- Bitemporal ECT (BTECT), 516
- Blood disorders, 296
- Borderline PD (BPD), 198–200
- BPRS. *See* Brief psychiatric rating scale (BPRS)
- Brain-derived neurotrophic factor (BDNF) and interleukin-6, 443
 protective mechanisms, 444
 thiobarbituric acid, 443
- Brief psychiatric rating scale (BPRS), 427, 508
- British Association for Psychopharmacology (BAP), 650
- Bulimia nervosa (BN), 257
- C**
- California Verbal Learning Test (CVLT), 111, 433
- Canadian Network for Mood and Anxiety Treatments (CANMAT)
 acute BD-I depression, 647
 acute manic episodes, 647
 maintenance treatment, monotherapy, 647
 psychiatric and somatic comorbidity, 647
- Cancer, 290–293
- Cardiovascular disease. *See* Vascular disease
- Caregiver and family burden
 classification, 368
 costs, 376–378
 depression and suicidality, 370
 description, 367–368
 feelings, 370–371
 household, social and leisure activities, 369
 interventions, 374–375
 manic symptoms, 374
 marriage, 372
 nature and quality, relationship, 370
 parenting, 370
 patient outcome, 375–376
 patient-related factors, 369
 prevalence, 368–369
 psychoeducation, 445
 psychological condition, 371

- relationships, 371–372
- schizophrenia, 374
- sociodemographic factors, 372–373
- stress, 368, 371
- suicidality, 373
- violence and aggression, 373–374
- work, 370
- Cataract, 311
- CBT. *See* Cognitive-behavioural therapy (CBT)
- Center for epidemiological studies-depression scale (CES-D), 425
- CG. *See* Complicated grief (CG)
- CGI. *See* Clinical global impression (CGI)
- CGI for bipolar disorder-depression (CGI-BP-D) scale, 526, 527
- Chronic fatigue syndrome, 306
- Chronic obstructive pulmonary disorder (COPD), 301
- Classification in psychiatry
 - anxiety, 425–426
 - anxious distress, 346
 - bipolar disorders, DSM-5, 343, 345–346
 - caregivers, 368
 - definition, mental disorder, 342
 - emotions, 28
 - ICD-6 edition, 342–343
 - ICD family, 343
 - ICD-10 vs. DSM-5, 346, 347
 - learning and memory structure, 115–116
 - mania (*see* Mania)
 - mixed episodes, DSM-5, 346
 - mood (affective) disorders, ICD-10, 343, 344
 - and nomenclature, 191
 - PDs, 198
 - plants and animals, 341
 - primary bipolar subtypes, 185–186
 - principle, 341
 - psychiatry, 341, 342
 - rapid cycling, 88
 - seasonality, 84
 - somatic syndrome, 346
- Clinical global impression (CGI)
 - asenapine, 526, 527
 - carbamazepine, 532
 - description, 428
 - lamotrigine, 533, 559
 - lithium, 556, 557
- CNCG. *See* Cross-National Collaborative Group (CNCG)
- Cognitive and functional remediation
 - euthymic BD patients, 633
 - meta-analytic reports, 633
 - neurocognitive techniques, 633
 - non-pharmacological methods, 633
 - schizophrenia, 633
- Cognitive-behavioural therapy (CBT)
 - antidepressant, 628
 - CBT vs. TAU, 628
 - emotive techniques vs. TAU, 628
 - maladaptive assumptions, 628
 - placebo, 628
 - post hoc analysis, 628
 - psychoeducation vs. TAU, 628
- Comorbidity
 - accidents and injuries, 311
 - adult BD patients, 225, 226
 - ‘artefactual comorbidity’, 225
 - Berkson’s bias, 225
 - bipolar males and females, 226
 - blood disorders, 296
 - cancer, 290–293
 - comorbid anxiety and depression, 225
 - dermatological disorders, 301, 305
 - description, 225
 - endocrinological disorders, 290, 294–296
 - epidemiological studies, 225
 - gastroenterological disorders, 296–300
 - genetics and endophenotypes, 311, 314
 - genitourinary disorders, 306, 310
 - immunological disorders, 301, 306, 307
 - infectious diseases (*see* Infectious diseases)
 - medical (*see* Medical comorbidity)
 - mental and medical, 226
 - musculoskeletal disorders, 306, 308–309
 - neurological conditions
 - BD-I inpatients, 277
 - brain MRI scan, 282
 - epilepsy, 284, 286, 287
 - headache, 277
 - migraine, 282, 284, 285
 - stroke, 282, 283
 - non-bipolar medical patients, 226
 - psychiatric (*see* Psychiatric comorbidity)
 - renal disorders, 311, 312
 - respiratory system disorders, 296, 301–304
 - systemic lupus erythematosus, 311, 313
 - vascular disease (*see* Vascular disease)
- Complicated grief (CG), 255
- COPD. *See* Chronic obstructive pulmonary disorder (COPD)
- Costs
 - aripiprazole and asenapine, 652
 - bipolar illness, 654
 - distribution, 378
 - employees, insurance, 377–378

- Costs (*cont.*)
 estimations, 376
 health care, 260
 hospitalization, 376–377
 medical and psychological care, 376
 olanzapine and divalproex, 569
 prescription medication, 377
 psychoeducation, 630
- Creativity
 ancient myths, 687–688
 artists and writers, 693
 BD rates, 693–694
 definition, 685
 development, 685, 687
 Ernest Hemingway, 688, 689, 691, 692
 families, 695
 geometry, 685, 686
 George Gordon Byron, 688, 690
 hand with reflecting sphere, 687
 isolated features, 696
 level, 694–695
 lifestyle and peculiarities, 695
 mania and hypomania, 695–696
 Margaux Louise Hemingway, 692–693
 neurocognitive function, 696
 reptiles, 685, 686
 Sir Isaac Newton, 688, 689
 technique and skills, 688
 treatment, 696–697
 Virginia Woolf, 688, 690
- Crohn's disease, 296
- Cross-National Collaborative Group (CNCG), 351–352
- Culture
 Cobb (1994), 698
 creativity (*see* Creativity)
 Devil and Daniel Johnston (2005), 698
 A Fine Madness (1966), 698, 699
 Frances (1982), 697
 Lust for Life (1956), 697
 Mad Love (1995), 699
 'manic depression', 700
 Mr Jones (1993), 698–699
 Running from Crazy (2013), 697
 suicide girls, 697, 698
- Cystitis, 306
- D**
- DAST. *See* Drug abuse screening test (DAST)
- Dermatological disorders, 301, 305
- Diabetes mellitus, 267, 270–271
- Disability
 approaches and models, 361–362
 CGI, 428
 clinical correlation, 364–365
 domains, functioning, 361
 education, 363
 GAF, GARF and SOFAS, 428–429
 Glo.Di.S, 429
 impairment, work, 363
 manic and depressive groups, 84
 medical conditions, 362
 medication, 366
 migraine, 282
 mood disorders, 362
 neurocognitive deficit, 365–366
 prevalence, 363–364
 PTSD, 246
 rapid cycling, 88
 schizophrenia, 366–367
 SF-36, 429
 stigma, 378, 379
 SUD, 214
 symptomatic recovery, 362–363
 VAS, 428
- Drug abuse screening test (DAST), 432
- Dyslipidaemia, 264, 267–269
- E**
- Eating disorder (ED), 255, 257–259
- Electroconvulsive therapy (ECT)
 acute bipolar mania, 471–474, 477, 478
 add-on treatment, 524, 550
 BFECT and BTECT group, 516
 vs. placebo condition, 502
- Emotion
 and affects, 28
 classification, 28
 etymology, 27
 evolutionary perspective, 30–31
 fear, 30
 'grief', 30
 and logical thinking, 29, 30
 modern neurobiological theory, 28–29
 'wheel (cone) of emotions', 28, 29
- Endocrinological disorders, 290, 294–296
- Endometriosis, 306
- Endophenotypes, 209–210
- EPA. *See* Ethyl-eicosapentaenoate (EPA)
- Epidemiology in psychiatry
 Amish Study, 348
 annual and lifetime rates, 355
 Australian Study, 353
 bipolar spectrum, 354–355
 Butajira Study, 353
 CNCG, 351–352
 description, 348–350
 ECA, 348, 351

- geriatric BD, 668–669
- NCS, 351
- Netherlands Study, 352–353
- Nottingham Study, 352
- paediatric BD, 664
- problems and limitations, 348
- schizophrenia, 347
- Shatin Study, 352
- smaller studies, 353–354
- SUD (*see* Substance use disorders (SUD))
- surveys, 348
- types, 347
- Zurich Switzerland, 352
- Epilepsy, 284, 286, 287
- EPS. *See* Extrapyrarnidal signs and symptoms (EPS)
- Ethyl-eicosapentaenoate (EPA), 583
- Evidence-based medicine (EBM), 643
- Executive function
 - BD-II patients, 131
 - description, 118–119
 - effect sizes, 115
 - and gender, 137
 - meta-analysis, 120, 139–140
 - mood symptoms, 128
 - neurocognitive impairment, 119–120, 128–129, 365
 - and neuropsychological tools, 111, 433
 - psychotic symptoms, 126
 - twin, 138
- Extrapyrarnidal signs and symptoms (EPS)
 - akathisia, 589
 - antipsychotics, 469
 - haloperidol treatment, 486, 488, 511
 - headache, 500
 - hyperprolactinaemia, 589
 - insomnia, 511
 - olanzapine-and asenapine-treated patients, 490
 - olanzapine group, 491
 - quetiapine IR, 492
 - risperidone, 512
 - ziprasidone treatment, 497, 498
- F**
- Family intervention
 - adjunctive family/multifamily group therapy, 632
 - efficacy vs. crisis management, 631
 - family-focused treatment, 631
 - hypomanic/manic episodes, 632
- Fibromyalgia, 306
- First-generation antipsychotics (FGAs), 518, 569, 589, 590, 592–593
- Free and Easy Wanderer Plus (FEWP), 484, 518, 532, 544
- G**
- GAF. *See* General assessment of functioning (GAF)
- Gamma aminobutyric acid (GABA)
 - synthesis, 467
- GARF. *See* General assessment of relational functioning (GARF)
- Gastroenterological disorders, 296–300
- GDS. *See* Geriatric depression scale (GDS)
- Gender
 - abdominal obesity, 660
 - comorbid conditions, 660
 - depressive symptoms, 659
 - migraine, 660
 - mood disorders, 659
 - neurocognitive function, 660
 - oral contraceptive, 659
 - spousal abuse, 659
 - subclinical hypothyroidism, 660
 - unipolar depression, 659
- General assessment of functioning (GAF), 428–429, 574
- General assessment of relational functioning (GARF), 428–429
- Generalized anxiety disorder (GAD)
 - comorbidity, 230, 231, 235–237
- Genitourinary disorders, 306, 310
- Genome-wide Association Scan (GWAS)
 - studies, 406, 407
- Geriatric BD
 - aetiopathogenetic mechanism, 671
 - antidepressant therapy, 670
 - comorbidity, 671
 - delirium, 672
 - dementia, 670
 - epidemiology
 - depression, 669
 - encephalopathy, 668
 - hypomania, 669
 - large-scale epidemiological data, 668
 - mania, 668
 - masking, 668
 - symptomatology, 669
 - factors, 669–670
 - geriatric mania, 670
 - masked depression, 671
 - neurocognitive impairment, 670
 - neurological disorders, 672
 - passive–aggressive/self-aggressive, 670

- Geriatric BD (*cont.*)
 passive suicide, 671
 pseudodementia, 670
 traumatic brain injury, 672
 treatment, 672–673
- Geriatric depression scale (GDS), 425
- Global disability scale (Glo.Di.S), 429
- Grief, 30, 31, 33, 35, 61, 255
- Guillain–Barre syndrome, 301
- GWAS studies. *See* Genome-wide Association Scan (GWAS) studies
- Gynaecologic problems, 306
- H**
- Hamilton anxiety rating scale (HAM-A)
 description, 426
 paroxetine, 535
 quetiapine, 536, 537, 585
- Hamilton depression rating scale (HAM-D), 422, 424
- Headache, 277
- Heart disease, 275, 277–281
- Hepatitis B and C (HCV), 286, 288–289
- Historical perspective
 affective episodes, 12–13
 ‘Anatomy of Melancholy’, 6, 8–9
 ancient Greeks, 4–5
 antipsychotics, 19
 Aretaeus of Cappadocia, 1, 4, 6
 Aristotle (384–322 BC), 5
 Avicenna (980–1037) Portrait, 6, 7
 Benjamin Rush (1745–1813), 9, 10
 body types, 13
 developments, 19, 21–23
 DSM and ICD, 14
 Ebers Papyrus, 1, 2
 electroconvulsive therapy (ECT), 15
 Emil Kraepelin (1856–1926), 12, 13
 etymology, mania, 2, 4
 fear and aggression, 5
 Galen (131–201 AD), 1, 3
 Hippocrates (460–370 BC), 1, 3
 Hippocratic texts, 1–2
 hyperthymias, 9
 involuntional melancholia, 12
 Jean-Philippe Esquirol (1772–1840), 9, 10
 Jean-Pierre Falret (1794–1870), 11
 Jules Baillarger (1809–1890), 11, 12
 lithium toxicity, 16, 17
 maintenance phase, lithium efficacy, 18–19
 manic depression, 14
 melancholia, 4
 mind–body dichotomy, 9
 Mogens Schou (1918–2005), 16, 17
 mood stabilizer, 19
 Paracelsus, 6, 7
 Pierre Deniker (1917–1999), 19, 20
 psychiatric indication, lithium, 15
 Roland Kuhn (1912–2005), 19, 20
 ‘Species Plantarum’, 9
 ‘unitary psychosis’, 11
 uric acid, 14
- Histrionic PD (HPD), 199, 200
- Human immunodeficiency virus (HIV), 286, 288–290
- Hyperlipidaemia, 267
- Hypertension, 272–274
- Hypomania
 definition, 51
 episodes, 51
 HCL-3, 425
 irritable, 170
- Hypomania/mania symptom checklist (HCL-32), 425
- Hypothyroidism, 290
- I**
- Immunological disorders, 301, 306, 307
- Infectious aetiology, 311
- Infectious diseases
 HCV, 286, 288–289
 HIV, 286, 288–290
- Inflammatory disease, 306
- Intelligence quotient (IQ)
 domains and tools used, neurocognitive, 110, 111
 learning and memory structure, 115
 mixed samples, relatives, 139
 neuropsychological tools, 432–433
 psychiatric hospital admissions, 111–112
 scores and performance, 110
 verbal (VIQ) and nonverbal/performance (PIQ), 112
- Intensive psychotherapy, 632–633
- International Society on Bipolar Disorders (ISBD). *See* Canadian Network for Mood and Anxiety Treatments (CANMAT)
- Interpersonal and social rhythm therapy (IPSRT), 630–632, 634, 636
- L**
- Learning
 acquisition, 117
 acute manic/mixed state, 117
 associative, 116
 classification, 115–116

- CVLT, 111, 433
 - in euthymic patients, 117
 - verbal, 116–117, 128–129
 - visual, 118
- Long-term course, BD patients
 - age, effect, 129–130
 - medication effect, 123–125
 - mood symptoms, 127–129
 - predominant polarity, 81–84
 - psychotic symptoms, 126–127
 - rapid cycling, 87–96
 - seasonality, 84–87
- M**
- MADRS score. *See* Montgomery–asberg depression rating scale (MADRS) score
- Maintenance treatment
 - add-on treatment, 574–576
 - aripiprazole, 570
 - carbamazepine, 569
 - combination treatment, 571–574
 - fluoxetine in BD-II patients, 570–571
 - lithium *vs.*
 - antidepressants, 567–568
 - carbamazepine, 565–566
 - lamotrigine, 567
 - SGAs, 568–569
 - valproate, 566–567
 - meta-analyses, 579–580
 - monotherapy (*see* Monotherapy, maintenance treatment)
 - olanzapine, 569–570
 - post hoc analyses, 576–579
 - RCT *vs.* lamotrigine, 570
 - and refractoriness, 461
 - valproate *vs.*
 - lithium, 569
 - olanzapine, 569
 - venlafaxine monotherapy, 570
 - YMRS and MADRS scores, 570
- Mammary dysplasia, 306
- Mania
 - accelerated psychomotor activity, 45–46
 - acute mania in patients, 50–51
 - chronic and unipolar, 50
 - classic mania, 44
 - delirious, 47
 - delusions, 48
 - hallucinations, 49
 - hypersexuality, 48
 - impulsivity and disinhibition, 47–48
 - irritability, 44, 45
 - lability, 44
 - patient's mood, 44
 - psychomotor component, 50
 - psychotic symptoms, 48–49
 - schizophrenia, 46
 - thinking and perception, 46–47
 - thought disorder, 46
- Manic symptoms, 230
- MAOIs. *See* Monoamine oxidase inhibitors (MAOIs)
- MCS. *See* Mental component summary (MCS)
- Medical comorbidity
 - diabetes mellitus, 267, 270–271
 - dyslipidaemia, 264, 267–269
 - general population, 260–263
 - hypertension, 272–274
 - metabolic syndrome, 272, 275, 276
 - obesity, 262, 264–266
- Medroxyprogesterone acetate (MPA), 520–521
- Memory
 - acute manic/mixed state, 117
 - autobiographical and prospective, 116
 - declarative and episodic, 116, 117
 - delayed, nonverbal and visual, 114, 116
 - in euthymic patients, 117
 - impairment and disability, 365–366
 - and learning, 115–116
 - meta-analysis, 139–140
 - and psychomotor functioning, 124
 - in relatives, 139
 - in twins, 138
 - WMS-LM, 111, 433
 - working, 114, 116
- Menstruation problems, 306
- Mental component summary (MCS), 551
- Mental disorders, 227–229
- Migraine, 282, 284, 285
- Mindfulness-based cognitive therapy (MBCT), 634
- Mindfulness-based training
 - fMRI, 634
 - MBCT, 634
- Minnesota multiphasic personality inventory 2nd edition (MMPI-2), 430
- Mixed episodes
 - acute episode
 - aripiprazole, 581
 - asenapine, 581
 - carbamazepine, 581
 - haloperidol/risperidone plus lithium/valproate, 581
 - OFC, 581
 - paliperidone, 581
 - risperidone, 581
 - ziprasidone, 581

- Mixed episodes (*cont.*)
 bipolar episode, 582
 clinical trials, bipolar depression, 581
 DSM-5, 581
 manic and depressive symptoms
 anhedonia and suicidality, 55
 antidepressants, 55–56
 description, 53
 DSM-IV and DSM-V, 52–53
 ‘dysphoric mania’ and ‘mixed agitated depression’, 54
 irritability and mood lability, 52
 mood, cognition and psychomotor activity, 53–54
 not-otherwise-specified (NOS)
 mood, 53
 psychotic and catatonic symptoms, 55
 racing thoughts, 55
- MMPI-2. *See* Minnesota multiphasic personality inventory 2nd edition (MMPI-2)
- Mondgomery–asberg depression rating scale (MADRS) score
 aripiprazole, 512
 asenapine, 490, 498, 514
 cariprazine, 500, 501
 description, 424
 divalproex, 531
 haloperidol, 486
 and HAM-D, 497, 532, 534
 lithium, 480, 530
 lurasidone, 539
 NAC group, 576
 and OFC, 570, 572
 olanzapine, 515
 and PANSS, 501, 507
 vs. placebo, 535–538
 quetiapine IR, 492, 526
 risperidone, 496, 512
- Monoamine oxidase inhibitors (MAOIs), 470
- Monotherapy, acute bipolar depression
 agents and therapeutic modalities, 539–540
 antidepressants, 533–535
 aripiprazole, 538
 carbamazepine, 532–533
 lamotrigine, 533
 lithium, 530–531
 lurasidone, 539
 olanzapine, 535–536
 quetiapine, 536–538
 treatment, 540
 valproate, 531–532
 ziprasidone, 539
- Monotherapy, acute mania
 lithium
 acute mania, 502
 antiepileptics (*see* Antiepileptics)
 antipsychotics (*see* Antipsychotics)
 electroconvulsive therapy, 502
 MADRS score, 480
 placebo-controlled study, 472, 477
 and quetiapine IR-treated patients, 479
 tamoxifen, 501
 therapeutic effect, 480
 transcranial magnetic stimulation, 502
 verapamil, 502
 withdrawal rate, 479
 YMRS score, 480
- Monotherapy, maintenance treatment
 antidepressants, 560–561
 aripiprazole, 562–563
 carbamazepine, 558
 fluoxetine in BD-II patients, 564
 lamotrigine, 558–560
 lithium, 555–558
 olanzapine, 561–562
 paliperidone, 563
 placebo-controlled, 564
 quetiapine, 563
 risperidone long-acting injectable, 564
 valproate, 558
- Mood
 anhedonia, 62, 64
 depressed mood, 62
 elevated mood, 64
 etymology, 27
 euphoria and euthymia, 64
 euthymia, 62
 expansive mood and emotional lability, 64
 irritable mood, 64
 modern approach, 27
 mourning, 62
 normal, 31
 pathological, 31–32
- MPA. *See* Medroxyprogesterone acetate (MPA)
- Musculoskeletal disorders, 306, 308–309
- N**
 N-acetyl cysteine (NAC), 576, 587
 Narcissistic PD (NPD), 199, 200
 National Cholesterol Education Program (NCEP), 272
 National Comorbidity Survey (NCS), 351

- National Institute of Clinical Excellence (NICE)
- acute mania, 650
 - antidepressant, 650
 - gabapentin and topiramate, 651
 - lithium and valproate, 650–652
 - olanzapine with fluoxetine (OFC), 652
 - paliperidone, 652
- NCS. *See* National Comorbidity Survey (NCS)
- NEO-personality inventory-3rd edition (NEO-PI-3), 430
- Neuroanatomy
- ACC and PFC, 393, 394
 - apolipoprotein D protein levels, 397–398
 - DT-MRI study, 395
 - grey matter loss, 395–396
 - limbic-cortical connections, 394–395
 - medial prefrontal cortex (mPFC), 398
 - neuron size, 397
 - non-pyramidal neurons, 397
 - psychological and biological factors, 393–394
 - schizophrenia, 396
 - synaptophysin, complexin II and GAP-43, 397
 - ventral and dorsal systems, 393
 - volumetric changes, 395
- Neurobiology
- ACC choline (Cho) and myoinositol (MI), 403
 - behavioural dysfunction, 401
 - biological markers, 405–406
 - dopamine receptors, 402
 - endophenotypes, 209–210
 - functional neuroimaging, 398–399
 - GABA, 403
 - genetic studies, 406–407
 - geriatric BD, 671–672
 - 5-HT-1A receptor, 402
 - 5-HT radioligand, 401
 - monoamine deficiency hypothesis, 400
 - muscarinic M2 receptors, 401
 - neuroanatomy, 393–398
 - NMDA receptors, 404–405
 - norepinephrine, 402
 - OCD, 249
 - pharmacological treatment, 399–400
 - unipolar depression, 401
- Neurocognitive deficit
- awareness, 136–137
 - clinical course, 136
 - deterioration, 134–135
 - as endophenotype
 - description, 137
 - executive function impairment, 139–140
 - first-degree relatives, 138
 - mixed samples, relatives, 139
 - reviews and meta-analyses, 140
 - twin studies, 138
- executive functioning, 133–134
- gender, 137
- illness onset, 134
- long-term evolution, 133, 134
- medication, 135
- neurodevelopmental factors, 136
- possibilities, 133
- Neurocognitive disorder
- description, 65–66
 - pseudodementia, 66
 - and substance use, 214
- Neurocognitive functions
- attention and concentration, 114–115
 - BD-II patients, 131–132
 - confounding factors, 110
 - domains and tools used, 110, 111
 - education, 131
 - executive function, 118–120
 - impairment, 59, 109
 - and IQ, 110–112
 - learning and memory, 115–117
 - long-term development, deficit (*see* Neurocognitive deficit)
 - medication effects, 123–125
 - mood symptoms, 127–129
 - psychiatric history, effect of age, 129–130
 - psychomotor and mental speed, 113–114
 - psychotic symptoms, 126–127
 - social cognition (*see* Social cognition)
 - verbal skills, 117–118
 - visuospatial skills, 118
- Neuropsychological tools, 432–433
- NMDA receptors. *See* N-methyl-d-aspartate (NMDA) receptors
- N-methyl-d-aspartate (NMDA) receptors
- GABA neurons, 403
 - genetics, 407
 - glutamatergic activity, 405
 - PSD-95 and SAP-102, 404–405
 - schizophrenia, 397
 - subunits, 404
- NPD. *See* Narcissistic PD (NPD)
- Number needed to harm (NNTH), 529, 553, 555
- Number needed to treat (NNT), 483, 491, 493, 498, 499, 515, 529, 553, 555

O

- Obesity, 262, 264–266
- Obsessive–compulsive disorder (OCD), 246, 249–250
- Otolaryngologic disorders, 311

P

Paediatric BD

- ADHD, 665–666
- auditory hallucinations, 665
- diagnosis, 664
- epidemiology, 664
- exacerbation, 665
- imitation and contagion, 664
- Italian vs. US bipolar children, 664
- mental health services, 664
- somatic complaints, 665
- treatment, 667–668

Panic disorder comorbidity, 237–240

Panic disorder severity scale (PDSS), 426

PANSS. *See* Positive and negative syndrome scale (PANSS)

Parkinson's disease, 282

PDSS. *See* Panic disorder severity scale (PDSS)

Peptic ulcer, 296

Personality disorders (PDs)

- anxiety and depression, 198
- ASPD, 199
- Axis II disorders, 198
- 'clinical syndromes', 198
- clusters, 198
- core characteristics, 197
- definition, 197
- DSM-5, 198
- euphoric mood, 201
- existential dilemata, 201
- grandiosity, 199
- HPD and NPD, 198–199
- inappropriate sexual seductiveness, 200
- interpersonal difficulties, 201
- mental disorders and conditions, 197
- mood symptoms, 199
- pervasive and excessive instability, 200
- pharmacological treatment, 201
- prevalence, NPD, 200
- psychiatric patients, 197
- psychodynamic and psychobiological model, 201
- spectrum approach, 200, 201
- systematic reviews, 200

Pharmacological treatment, 201, 346, 366, 399–400, 540, 584, 627, 662

PMDD. *See* Premenstrual dysphoric disorder (PMDD)PMS. *See* Premenstrual syndrome (PMS)

Polycystic ovary syndrome, 306

Positive and negative syndrome scale (PANSS), 120, 427

Post-traumatic stress disorder (PTSD), 246–248

Predominant polarity

- alcohol abuse/substance abuse, 84
- BAP, 650
- depressive (DPP) vs. manic (MPP), 82, 83
- description, 81
- disability, 84
- psychiatric comorbidity, 84
- staging, BD, 439, 441
- types, 81–82

Premenstrual dysphoric disorder (PMDD), 260

Premenstrual syndrome (PMS), 260

Psychiatric comorbidity

- ADHD, 227, 250–256
- anxiety (*see* Anxiety) and BD-II, 260
- BD patients, 226–227
- CG, 255
- conditions, 257–260
- cross-sectional, 227
- ED, 255, 257–259
- manic and hypo-manic episodes, 227
- mental disorders, 227–229
- OCD, 246, 249–250
- 'residual' symptomatology, 226
- under-recognition and-treatment, 226

Psychoeducation

- Barcelona group, 629, 630
- beneficial effect, 629
- dialectical behaviour therapy, 630
- habits, 629
- likelihood of relapse, 630
- multicomponent care packages, 630
- multimodal approaches, 630
- vs. non-specific group, 629
- reduction of symptoms, 630
- social rhythms, 630
- stress management, 629

Psychological theories

- aggression-turned-inward model, 391
- cognitive model, 392
- depression and reinforcement, 393
- learned helplessness model, 392
- maladaptive patterns, 390–391
- mania, 390
- neurobiology (*see* Neurobiology)

- object loss, 391
 - self-esteem, 392
 - Psychological treatments, characteristics, 667
 - Psychometric tools
 - AIMS, 431
 - ASI, 432
 - AUDIT, 431–432
 - BDI-I, 424
 - Bech-Rafaelsen MRS, 425
 - BPRS, 427
 - CAGE, 431
 - CES-D, 425
 - DAST, 432
 - description, 421–422
 - disability (*see* Disability)
 - domains, 422–424
 - GDS, 425
 - HAM-A and PDSS, 426
 - HAM-D, 422, 424
 - HCL-32, 425
 - MADRS, 424
 - MMPI-2, 430
 - NEO-PI-3 and TCI, 430
 - PANSS, 427
 - SAFTEE, 430–431
 - SAPS/SANS, 427–428
 - Simpson–Angus rating scale, 431
 - STAI-Y, 426–427
 - TEMPS-A, 429–430
 - UKU-SERS, 431
 - YBOCS, 426
 - YMRS, 425
 - ZDRS, 424
 - Psychomotor disorder
 - acceleration and agitation, 65
 - catatonia and fatigue, 65
 - crowded thoughts, 65
 - flight of ideas, 64
 - racing thoughts, 64
 - slowing and stupor, 65
 - Psychosocial interventions
 - psychiatric morbidity, 636
 - rehabilitative interventions, 636
 - schizoaffective disorder, 636
 - Psychosocial treatment
 - adjunctive psychotherapies, 627
 - background, 627–628
 - BD patients, chronic mood symptoms, 627
 - CBT, 634
 - clinical severity and cognitive dysfunction, 627
 - IPSRT *vs.* intensive clinical management, 631, 634
 - subsyndromal symptoms, 627
 - Psychotic features
 - acute bipolar depression, 58
 - Bell's mania, 58–59
 - delusions, 57
 - depressive mood-congruent hallucinations, 67, 68
 - insight, 68
 - manic mood-congruent hallucinations, 67, 68
 - manic patients, 57
 - 'melancholia gravis', 58
 - mood-incongruent delusions, 67–68
 - nihilistic delusions, 67
 - schizoaffective disorder, 56
 - PTSD. *See* Post-traumatic stress disorder (PTSD)
- Q**
- Quality of life (QoL)
 - adverse effects, 366
 - caregivers, 369, 375
 - chronic impairment, 362
 - comorbid anxiety, 230
 - depressive symptoms, 367
 - gambling, 207
 - life satisfaction, 367
 - lurasidone, 539, 547
 - olanzapine and OFC, 551
 - pharmacological treatment, 366
 - psychoeducation, 630
 - PTSD, 246
 - quetiapine, 551–552
 - schizophrenia, 367
 - SF-36, 429
 - temperaments, 173
 - TMAP, 648
- R**
- Rapid cycling BD patients
 - acute episodes, treatment, 582
 - acute mania, 582
 - acute mixed episodes and bipolar mania/mixed, 475, 477
 - age-of-onset effect, 91
 - alcohol and drug abuse, 91
 - antidepressants use, 94–95
 - and comorbid drug abuse, 257
 - cycle length and illness progression, 89
 - description, 34–35, 87
 - efficacy against acute bipolar depression, 89–90, 478

- Rapid cycling BD patients (*cont.*)
 exacerbation, emotional
 endophenotypes, 96
 and female gender, 92–93
 and hypothyroidism, 93–94
 ‘kindling’ mechanism, 92
 labile emotion, 90
 long-term course, 582
 maintenance treatment, 475, 476
 medical conditions, 93
 mood fluctuations, 88
 olanzapine, use, 526
 ‘personalized psychiatry’, 88
 premenstrual tension syndrome, 91–92
 prevalence rates, 89, 93
 prolonged periods, 88
 relapse prevention, 583–584
 stages, 440
 substance abuse and suicidality, 95
 ultrarapid and ultradian cycling, 87–88
- Renal disorders, 311, 312
- Respiratory system disorders, 296, 301–304
- Rheumatoid arthritis, 306
- Risperidone long-acting injectable (RLAI),
 561–562, 564, 575
- rTMS. *See* Transcranial Magnetic
 Stimulation (rTMS)
- S**
- SAFTEE. *See* Systematic assessment of
 treatment-emergent events
 (SAFTEE)
- Scale for the assessment of negative symptoms
 (SANS), 352, 427–428
- Scale for the assessment of positive symptoms
 (SAPS), 427–428
- Schizoaffective disorder
 circular disorders, 189
 comparison, schizophrenia, 192
 dementia praecox, 189
 description, 193
 DSM-5, 56
 DSM-I, 191
 genetic studies, 192–193
 hallucinations, 48
 ICD-10, 191
 interforms, 190
 lithium vs. carbamazepine, 565
 mixed mood episodes, 192
 mood symptoms, 190
 neurocognitive impairment and
 deficits, 192
 nomenclature and classification, 191
 psychotic symptoms, 190
 ‘recovered schizophrenics’, 189–190
 schizophreniform psychoses, 189
 weaknesses, 190
- Schizophrenia, 267
- Seasonality
 depression during autumn–winter, 85
 description, 84–85
 hemispheres, 86
 hospitalizations, 86
 lithium level, plasma, 85–86
 meteorological conditions, 87
 somatic symptoms, 69
- Second-generation agents (SGAs), 469, 553,
 568–569, 593
- Selective serotonin reuptake inhibitors
 (SSRIs), 470, 577, 592
- Serotonin–norepinephrine reuptake inhibitors
 (SNRIs), 470
- Serotonin transporter (SERTPR), 592
- Short form-36 items (SF-36), 429
- SILENT. *See* Syndrome of irreversible
 lithium-effected neurotoxicity
 (SILENT)
- Simple (specific) phobia comorbidity, 237,
 241, 242
- Social and occupational functioning
 assessment scale (SOFAS),
 428–429
- Social anxiety disorder (social phobia), 241,
 243–246
- Social cognition
 decision-making, emotional, 122
 description, 120
 emotion processing, 121–122
 meta-analysis, 122–123
 ToM, 121
- Social cognition and interaction training
 (SCIT), 633
- SOFAS. *See* Social and occupational
 functioning assessment scale
 (SOFAS)
- Soluble tumour necrosis factor receptor type 1
 (sTNF-R1), 443
- Somatic comorbidity, 261
- Somatic complaints
 anorexia and weight loss, 68
 circadian dysregulation, 69
 hyposomnia and hypersomnia, 69
 insomnia, 68–69
 seasonality, 69
 sexual desire and activity, 70
 sexual dysfunction, 69–70
 weight gain, 68

- SSRIs. *See* Selective serotonin reuptake inhibitors (SSRIs)
- Staging
- anatomical changes, 445
 - BDNF, TNF-alpha and interleukins, 443
 - cellular mechanisms, 442
 - clinical features, 440–441
 - description, 437–438, 451
 - DNA damage, 444–445
 - feasibility, 437
 - glutathione S-transferase and reductase, 443
 - hypothesis, mania, 443–444
 - inflammatory cytokines, 443
 - 'kindling effect', 438
 - manic–depressive illness, 438–439
 - medications, 438
 - models
 - Berk, 446, 449
 - Cosci and Fava, 450
 - description, 446–448
 - Frank, 450–451
 - Kapczinski, 449
 - Post, 449–450
 - neuroimaging data, 442
 - neurotoxicity, 444
 - 3-nitrotyrosine levels, 443
 - prodromal symptoms, 438
 - protective mechanisms, 444
 - psychiatric diagnosis, 437
 - psychotic features, 440
 - rapid cycling, 440
 - treatment data, 445–446
- State–trait anxiety inventory-form Y (STAI-Y), 426–427
- Stigma
- caregivers, 368, 378–379
 - description, 378
 - medical comorbidity, 260–261
 - schizophrenia, 697
- Stroke, 282, 283
- Substance use disorders (SUD), 584–585
- and alcohol use disorder (*see* Alcohol use disorders)
 - BD-II patients, 205
 - cannabis use disorder, 207, 212–213
 - causative factors and mechanisms, 208–209
 - cause and effect, 205
 - clinical features, 210
 - cocaine, 207, 213
 - comorbidity, 214
 - disability, 214
 - gambling, 207
 - legal issues, 215
 - methadone, 207
 - neurobiology, 209–210
 - neurocognitive disorder, 214
 - nicotine use and smoking, 208, 213–214
 - obesity, 211
 - opioids, 208, 213
 - prevalence, 205–206
 - primary prevention, 210–211
 - self-report scales, 431
 - suicidality, 214–215
 - treatment, 215–216, 584–585
- SUD. *See* Substance use disorders (SUD)
- Suicidality
- aetiology, 660
 - antidepressants, 662, 663
 - chronic depression, 661
 - FDA, 662
 - lamotrigine, 663
 - lithium, 663
 - medication adverse effects, 662
 - multi-causal behaviour, 660
 - pharmacological treatment, 662
 - prevention, 661
 - psychological autopsy, 661
 - sophisticated approach, 660
 - SSRIs prescriptions, 662
 - subthreshold depressive symptoms, 661
 - uncontrolled observational data, 663
 - victims, 661
- Superoxide dismutase (SOD) activity, 444
- Syndrome of irreversible lithium-effected neurotoxicity (SILENT), 466
- Systematic assessment of treatment-emergent events (SAFTEE), 430–431
- Systemic lupus erythematosus, 311, 313
- T**
- TBARS. *See* Thiobarbituric acid reactive substances (TBARS)
- TCAs. *See* Tricyclic antidepressants (TCAs)
- TCI. *See* Temperament and character inventory (TCI)
- Temperament
- affection, 54, 173–174
 - ancient approach, 163
 - assessment, 169
 - Avicenna (980–1037), 6, 7
 - BD-II patients, 169–170
 - bipolar clinical features, 171, 172
 - bipolar spectrum, 182, 183
 - characteristics, 167
 - chromosomes, 407
 - clinical constellation, 169

- Temperament (*cont.*)
- cluster B personality disorders, 173
 - depressed patients, 170
 - diagnosis and treatment, 174
 - dysthymic, cyclothymic and anxious, 169
 - empirical research, 167, 168
 - gender differences, 171
 - health and mortality, 168
 - human behaviour, 173
 - hyperthymic and depressive, 174
 - neurotic, characterological and existential depressions, 73
 - neuroticism, 374
 - patient's relatives, 172–173
 - personality traits, 167–168
 - physiology and medicine, 167
 - psychoticism, 167
 - psychotic mixed patients, 170
 - suicide attempts, 170–171
 - theoretical elaboration, 163–166
 - types, 163
 - unipolar and bipolar depressive patients, 169, 171
- Temperament and character inventory (TCI), 430
- Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego Autoquestionnaire (TEMPS-A), 429–430
- Texas medication algorithm project (TMAP)
- antidepressant medication, 648
 - antimanic agents, 648
 - BD-II and rapid cycling disorder, 648
 - mania/hypomania, 648
 - mood stabilizers, 648
 - nomenclature, 648
 - olanzapine, 648
 - TDMHMR system, 648
- Theory of mind (ToM)
- deficits, 122–123
 - description, 120
 - effect size, 112
 - and neuropsychological tools, 111, 433
 - and social cognition, 121
- Thiobarbituric acid reactive substances (TBARS), 444
- Thought disorder
- Clang association, 66
 - depressive thought content, 66
 - description, 37
 - guilt and death, 66–67
 - Kurt Schneider's theory, 37
 - in manic patients, 46
 - manic thinking, 67
 - suicidal, 38
 - suicidal ideation, 67
- ToM. *See* Theory of mind (ToM)
- Tourette's disorder, 260
- Transcranial Magnetic Stimulation (rTMS), 502, 540
- Treatment guidelines
- benefits, 643–644
 - classification systems, 643
 - combination therapy, 654
 - Consensus Development Conferences, 644
 - EBM, 643
 - efficacy and safety, 651
 - ethical dilemmas, 644
 - evidence-based guidelines, 653, 654
 - hypomania, 653
 - mental disorders, 654
 - modafinil, 652
 - monotherapy, 651–652
 - olanzapine, 653
 - psychiatric community, 654
 - skills, 644
 - standard approach, 643
 - supplementary method, 643
- Tricyclic antidepressants (TCAs), 470, 592
- U**
- Unipolar depression, 231
- US Food and Drug Administration (FDA), 468, 662, 663
- V**
- Vascular disease
- antipsychotic medication, 275
 - BD-I and BD-II patients, 275
 - cardiovascular risk, 275
 - heart disease, 275, 277–281
 - mortality among BD patients, 275
- Visual analogue scale (VAS), 428, 429
- W**
- Wechsler Memory Scale-Logical Memory (WMS-LM), 111, 433
- World Federation of Societies of Biological Psychiatry (WFSBP) guidelines
- evidence-based pharmacotherapy and evidence-based psychiatry, 650
 - metabolic syndrome, 649
 - PORT method, 649

quetiapine, 649
treatment, acute mania, 649, 652
valproate and lamotrigine, 652–653
verapamil, 649

Y

Yale–Brown obsessive–compulsive scale
(YBOCS), 426

Young mania rating scale (YMRS) score
allopurinol, 515

aripiprazole, 493–494, 506–507, 527
description, 425

haloperidol-treated patients, 488, 490, 511
and HAM-D, 535–536

lithium, 479

and MADRS scores, 570, 572

olanzapine-treated patients, 489, 515

oxcarbazepine, 522

paliperidone ER, 499

placebo group, 481, 488

quetiapine IR-treated patients, 486, 491,
492, 499, 523, 526

risperidone-treated patients, 494–495

tamoxifen-treated patients, 501

valproate, 482, 508, 515, 521

Z

Zung depression rating scale (ZDRS), 424